Compare CETX & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CETX | VYNE |
|---|---|---|
| Founded | 1998 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.5M | 19.0M |
| IPO Year | 1998 | 2018 |
| Metric | CETX | VYNE |
|---|---|---|
| Price | $1.42 | $0.59 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 418.2K |
| Earning Date | 02-13-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $76,488,088.00 | $524,000.00 |
| Revenue This Year | $20.41 | N/A |
| Revenue Next Year | N/A | $16.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.39 | 6.29 |
| 52 Week Low | $1.36 | $0.28 |
| 52 Week High | $42.60 | $2.94 |
| Indicator | CETX | VYNE |
|---|---|---|
| Relative Strength Index (RSI) | 36.98 | 68.94 |
| Support Level | $1.37 | $0.55 |
| Resistance Level | $1.60 | $0.57 |
| Average True Range (ATR) | 0.15 | 0.02 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 10.38 | 91.01 |
Cemtrex Inc is a multi-industry technology company. It has expanded into a range of sectors, including smart technologies, virtual and augmented realities, industrial solutions, and intelligent security systems. The company's operating segment includes the Security segment and the Industrial Services segment. The security segment provides end-to-end security to all industrial, corporate, and governmental security via its owned subsidiary, Vicon. Whereas the AIS part Industrial Service Segment is expertise services for rigging, millwrighting, in-plant maintenance, equipment erection, relocation, and disassembly to diversified customers. It generates maximum revenue from the Industrial Service Segment, and from the USA. It also operates UK, USA, and Other.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.